Evidence map›Paper›PMID 27400742›Full record

ArticleBMC complementary and alternative medicine2016

Use of complementary and alternative medicines in haemodialysis patients: a cross-sectional study from Palestine.

Sa'ed H Zyoud, Samah W Al-Jabi, Waleed M Sweileh, Ghada H Tabeeb, Nora A Ayaseh, Mayas N Sawafta, Razan L Khdeir, Diana O Mezyed, Dala N Daraghmeh, Rahmat Awang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary and alternative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
12.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sa'ed H ZyoudPoison Control and Drug Information Center (PCDIC), College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. saedzyoud@yahoo.com.
Samah W Al-JabiDepartment of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Waleed M SweilehDepartment of Pharmacology and Toxicology, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Ghada H TabeebPharmD program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Nora A AyasehPharmD program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Mayas N SawaftaPharmD program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Razan L KhdeirPharmD program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Diana O MezyedPharmD program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Dala N DaraghmehPharmD program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Rahmat AwangWHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM), Penang, 11800, Malaysia.
An-Najah National University · PSUniversiti Sains Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComplementary and alternative medicine (CAM), and herbal therapies, are accepted worldwide, and have been important from medical, sociological and economic perspectives, among haemodialysis (HD) patients. The primary aim of this study was to evaluate the use of CAM among patients with end-stage renal disease (ESRD) who are undergoing HD.

methodsFace-to-face interviews of patients with ESRD undergoing HD from ten outpatient renal departments at a national level in Palestine were conducted from June 2014 to January 2015. A survey questionnaire, which included questions on socio-demographic and clinical characteristics, and on the CAM therapies that were used, was administered.

resultsOut of 267 patients interviewed, 172 patients used at least one type of CAM in the last month prior to the interview, and thus the utilisation rate was 64.4 %. Forty one (15.4 %) patients reported using one type of CAMs, while 18.7 % used two different CAMs and 30.3 % used more than two types of CAMs for their health status. Of the patients who used CAM, herbal therapies were used most often (43.5 %), followed by honey (35.6 %), diet (22.8 %), and exorcism in Islam (16.9 %). The herbal therapies mentioned most often were Nigella sativa L. (18.7 %), followed by Salvia officinalis L. (16.9 %), and Pimpinella anisum L. (10.5 %).

conclusionsIn conclusion, the prevalence of CAM is relatively high in the selected population. Most patients used biological therapies such as herbal remedies, thus highlighting a greater need for patient education regarding CAM therapies and possible herb-drug interactions. Health care providers must be aware of the potential benefits and risks related to CAM use. There is a need for more clinical research pertaining to CAM to reach stronger evidence regarding potential benefits and risks related to CAM use.

Indexed as

AdultAgedArabsComplementary TherapiesCross-Sectional StudiesFemaleHumansKidney Failure, ChronicMaleMiddle AgedMiddle EastPhytotherapyRenal DialysisSocioeconomic FactorsComplementary and alternative medicineEnd-stage renal diseaseHaemodialysisHerbal medicinePalestine

Identifiers

PMID27400742
PMCPMC4940841
OpenAlexW2473506037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.